A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence (original) (raw)
Ruxolitinib Remains Effective in Myelofibrosis after the Necessary Dose Reductions: Real-Life Data from a Multi-Center Observational Study
Evdoxia Hatjiharissi
Blood, 2016
View PDFchevron_right
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Richard Silver
Journal of hematology & oncology, 2017
View PDFchevron_right
Recommendations on the use of ruxolitinib for the treatment of myelofibrosis
Pierre Zachée
Hematology
View PDFchevron_right
Comparison Study between Real Life and Published Data Outcome among Myelofibrosis Patients Who are Using Ruxolitinib at King Abdulaziz Medical City-Central Region
Ahmed Elmubark
Ahmed Elmubark, 2020
View PDFchevron_right
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis
Nicholas Sarlis
Haematologica, 2015
View PDFchevron_right
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Richard Silver
Haematologica, 2015
View PDFchevron_right
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study
Catherine Bouard
Leukemia & Lymphoma, 2020
View PDFchevron_right
Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey
emin kaya
TURKISH JOURNAL OF MEDICAL SCIENCES, 2021
View PDFchevron_right
Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I
Richard Silver
Blood, 2012
View PDFchevron_right
Real-life ruxolitinib experience in intermediate-risk myelofibrosis
I. Kaygusuz
Blood Research, 2021
View PDFchevron_right
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
Richard Silver
British Journal of Haematology, 2013
View PDFchevron_right
Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
Kevin Hou
Journal of Hematology & Oncology, 2018
View PDFchevron_right
Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
Richard Silver
Journal of Clinical Oncology, 2013
View PDFchevron_right
Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis
Francesco Mendicino
Future oncology (London, England), 2015
View PDFchevron_right
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial
Heike Pahl
Annals of Hematology
View PDFchevron_right
Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis
kate burbury
Blood, 2020
View PDFchevron_right
A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis
John Mascarenhas
Blood, 2013
View PDFchevron_right
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of ERNEST Study
Arianna Masciulli
Blood Advances
View PDFchevron_right
Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly
Ohad Benjamini
Blood, 2012
View PDFchevron_right
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
Nicola Polverelli
Hematological oncology, 2017
View PDFchevron_right
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice
Francesco Mendicino
Annals of Hematology
View PDFchevron_right
Descriptive, Comparative Study of Filipino Myelofibrosis Patients: An Agematched Comparison of Patients on Ruxolitinib vs. Best Available Therapy
Priscilla B Caguioa
Journal of Hematology & Thromboembolic Diseases, 2014
View PDFchevron_right
Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis
Tuochuan Dong
Haematologica, 2019
View PDFchevron_right
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
Alessandro Vannucchi
Journal of hematology & oncology, 2017
View PDFchevron_right
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Richard Silver
New England Journal of Medicine, 2012
View PDFchevron_right
PHARMACOECONOMIC EVALUATION OF RARE DISEASE MANAGEMENT IN PRIMARY MYELOFIBROSIS TREATMENT WITH RUXOLITINIB
Vyacheslav Serpik
PHARMACOECONOMICS: theory and practice, 2015
View PDFchevron_right
Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system
Vincenzo Accurso
Drugs in Context
View PDFchevron_right
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study
Pilar Giraldo
Hematological Oncology, 2021
View PDFchevron_right
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
Nicola Polverelli
Oncotarget, 2017
View PDFchevron_right
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis
Alfredo Molteni
Blood Advances, 2022
View PDFchevron_right
Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance
Francesco Mendicino
Current Oncology
View PDFchevron_right